Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Jonathan S Cebon

11PUBLICATIONS

99CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersInnate immunity

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (11)

Sort by Publication Date:

|Apr 24, 2026

Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial.

|Sep 11, 2025

Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial.

Adithya Balasubramanian, Claire Marceaux, Sehrish Kanwal

|Jul 02, 2021

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.

Georgina V Long, Caroline Robert, Marcus O Butler

|Sep 17, 2020

Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma.

Pouya Faridi, Katherine Woods, Simone Ostrouska

|Jul 02, 2020

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.

Matteo S Carlino, Alexander M Menzies, Victoria Atkinson

|Jun 26, 2020

Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma.

Jennifer Eom, Saem Mul Park, Vaughan Feisst

Pageof 2

Frequent Collaborators

5 joint publications

Andreas Behren

3 joint publications

Jodie Palmer

2 joint publications

Ashray Gunjur

2 joint publications

Simone Ostrouska

2 joint publications

Katherine Woods

2 joint publications

Jane Y So

2 joint publications

Weisan Chen

2 joint publications

Michael Michael

2 joint publications

P Rod Dunbar

2 joint publications

Damien Kee

Frequent Collaborators

5 joint publications

Andreas Behren

3 joint publications

Jodie Palmer

2 joint publications

Ashray Gunjur

2 joint publications

Simone Ostrouska

Top Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on : Feb 14, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on : Apr 22, 2019

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on : Feb 07, 2021

See more related videos

Top Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on : Feb 14, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on : Apr 22, 2019

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on : Feb 07, 2021

See more related videos